Shiv K Sarin1, Manoj Kumar2. 1. Department of Hepatology, Institute of Liver and Biliary Sciences, D1 Vasant Kunj, New Delhi, India. shivsarin@gmail.com. 2. Department of Hepatology, Institute of Liver and Biliary Sciences, D1 Vasant Kunj, New Delhi, India.
Abstract
BACKGROUND: There is much controversy surrounding the natural history of hepatitis C virus (HCV) infection. AIMS: The aim of this review was to review the natural history of HCV infection. METHODS: Published English literature was searched via pubmed and then reviewed. RESULTS: Approximately, 75-85% of HCV-infected persons will progress to chronic HCV infection. The rate of chronic HCV infection is affected by a person's age, gender, race, and viral immune response. Once chronic HCV infection develops, there are external and host factors that can increase the risk of progression of liver disease. Progression of chronic HCV infection is not linear in time, probably because many cofactors change the rate of development of fibrosis, cirrhosis, and hepatocellular carcinoma. Factors linked with aggressive disease progression include age at infection, duration of infection, heavy alcohol use, co-infections with HIV or hepatitis B virus, male sex, steatosis, insulin resistance (and factors associated with the metabolic syndrome), and host genetics. However, the relative importance of many and varied factors remains uncertain, and further research efforts should be directed toward design of predictive models for effective risk stratification. Interferon-based therapy, particularly among those achieving a sustained virologic response (SVR), is associated with improved fibrosis and inflammation scores, reduced incidence of hepatocellular carcinoma, and prolonged life expectancy. CONCLUSIONS: Despite the progress in understanding the factors affecting the natural history of HCV infection, a great deal remains to be learnt.
BACKGROUND: There is much controversy surrounding the natural history of hepatitis C virus (HCV) infection. AIMS: The aim of this review was to review the natural history of HCV infection. METHODS: Published English literature was searched via pubmed and then reviewed. RESULTS: Approximately, 75-85% of HCV-infectedpersons will progress to chronic HCV infection. The rate of chronic HCV infection is affected by a person's age, gender, race, and viral immune response. Once chronic HCV infection develops, there are external and host factors that can increase the risk of progression of liver disease. Progression of chronic HCV infection is not linear in time, probably because many cofactors change the rate of development of fibrosis, cirrhosis, and hepatocellular carcinoma. Factors linked with aggressive disease progression include age at infection, duration of infection, heavy alcohol use, co-infections with HIV or hepatitis B virus, male sex, steatosis, insulin resistance (and factors associated with the metabolic syndrome), and host genetics. However, the relative importance of many and varied factors remains uncertain, and further research efforts should be directed toward design of predictive models for effective risk stratification. Interferon-based therapy, particularly among those achieving a sustained virologic response (SVR), is associated with improved fibrosis and inflammation scores, reduced incidence of hepatocellular carcinoma, and prolonged life expectancy. CONCLUSIONS: Despite the progress in understanding the factors affecting the natural history of HCV infection, a great deal remains to be learnt.
Authors: A Kasahara; H Tanaka; T Okanoue; Y Imai; H Tsubouchi; K Yoshioka; S Kawata; E Tanaka; K Hino; K Hayashi; S Tamura; Y Itoh; K Kiyosawa; S Kakumu; K Okita; N Hayashi Journal: J Viral Hepat Date: 2004-03 Impact factor: 3.728
Authors: Tarik Asselah; Ivan Bièche; Ingrid Laurendeau; Valérie Paradis; Dominique Vidaud; Claude Degott; Michelle Martinot; Pierre Bedossa; Dominique Valla; Michel Vidaud; Patrick Marcellin Journal: Gastroenterology Date: 2005-12 Impact factor: 22.682
Authors: M Yano; H Kumada; M Kage; K Ikeda; K Shimamatsu; O Inoue; E Hashimoto; J H Lefkowitch; J Ludwig; K Okuda Journal: Hepatology Date: 1996-06 Impact factor: 17.425
Authors: Nabil Antaki; Antonio Craxi; Sanaa Kamal; Rami Moucari; Schalk Van der Merwe; Samir Haffar; Adrian Gadano; Nizar Zein; Ching Lung Lai; Jean-Michel Pawlotsky; E Jenny Heathcote; Geoffrey Dusheiko; Patrick Marcellin Journal: Liver Int Date: 2009-12-10 Impact factor: 5.828
Authors: E Silini; F Bono; A Cividini; A Cerino; S Bruno; S Rossi; G Belloni; B Brugnetti; E Civardi; L Salvaneschi Journal: Hepatology Date: 1995-02 Impact factor: 17.425
Authors: Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin Journal: Science Date: 2007-07-06 Impact factor: 47.728
Authors: D Prati; C Capelli; A Zanella; F Mozzi; P Bosoni; M Pappalettera; F Zanuso; L Vianello; E Locatelli; C de Fazio; G Ronchi; E del Ninno; M Colombo; G Sirchia Journal: Gastroenterology Date: 1996-01 Impact factor: 22.682